Simultaneous TGF-β and GITR pathway modulation promotes anti-tumor immunity in glioma

Key Points

• Tumor immunity improves with simultaneous TGF-β and GITR pathway modulation, enhancing immune response.
• Significant increases in immune cell infiltration and cytokine production observed at 14 days post-intervention.
• Assessment using pathway modulation approaches reveals promising outcomes in glioma treatment.
• Potential therapeutic strategies need further validation through clinical trials and preclinical models.